Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, … Continue reading Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of … Continue reading Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is up over 16% today on news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock performance was 14.30% in last session and finished the day at $48.67. Traded volume was 435,645.00million shares in the last session and the average volume of the … Continue reading Healthcare Stocks In News: Ultragenyx (NASDAQ:RARE), Flexion (NASDAQ:FLXN), Receptos Inc (NASDAQ:RCPT), Acorda Therapeutics (NASDAQ:ACOR), Aratana Therapeutics (NASDAQ:PETX)

CDK Global, Inc. (NASDAQ:CDK), the largest provider of integrated information technology and digital marketing and advertising solutions to the automotive industry, plans to expand its presence in downtown Detroit. The firm will lease additional space to provide advanced digital marketing insights and services for its clients in the automotive industry. The project will generate a total capital investment of nearly $3.6 million and add 100 … Continue reading Investors Are Watching : CDK Global (NASDAQ:CDK), Alpha Natural Resources (NYSE:ANR), Ultragenyx Pharmaceutical (NASDAQ:RARE), Titan Machinery (NASDAQ:TITN), Golar LNG Partners (NASDAQ:GMLP)

Bayer has completed the global acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals. “This acquisition is a milestone for Bayer and we intend to continue the expansion of our attractive over-the-counter business both through organic growth and bolt-on acquisitions,” explained … Continue reading Stock Runners : Merck & Co. Inc. (NYSE:MRK), Trinity Industries Inc. (NYSE:TRN), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), WellCare Health Plans, Inc. (NYSE:WCG), LRAD

Ultragenyx Pharmaceutical (NASDAQ:RARE) SVP Thomas Richard Kassberg unloaded 20,000 shares of the stock on the open market in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $53.91, for a total transaction of $1,078,200.00. Following the sale, the senior vice president now directly owns 105,804 shares in the company, valued at approximately $5,703,894. The sale was disclosed in … Continue reading Investors Are Watching : Ultragenyx Pharmaceutical (NASDAQ:RARE), Bankrate, Inc. (NYSE:RATE), American Shared Hospital Services (NYSEMKT:AMS), Calamos Asset (NASDAQ:CLMS), Canadian National Railway (NYSE:CNI)